Proteome Sciences (LON:PRM) is up big today on the markets after announcing success in its project to develop better diagnostic tools for Alzheimer’s disease.
The Company announced that in collaboration with the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health and Merck Millipore, the completion of the large, 1,000 sample Alzheimer’s Disease (AD) biomarker validation study. Preliminary results indicate that these biomarkers have significant potential diagnostic and prognostic utility that could form the basis of a series of simple blood tests for the diagnosis and management of this debilitating disease.
All American Investor
Showing posts with label Proteome Sciences. Show all posts
Showing posts with label Proteome Sciences. Show all posts
Wednesday, March 28, 2012
Subscribe to:
Posts (Atom)